Amniocentesis (AC) is considered the best option for prenatal diagnosis (PD) of fetal cytomegalovirus (CMV) infection. To reduce the risk of false negative results, it is recommended to perform AC not before completed 21 weeks of gestation (WG) and >6 weeks from maternal infection.
Amniocentesis (AC) is considered the best option for prenatal diagnosis (PD) of fetal cytomegalovirus (CMV) infection. To reduce the risk of false negative results, it is recommended to perform AC not before completed 21 weeks of gestation (WG) and >6 weeks from maternal infection. 1, 2 In a recent publication, we described a single centre experience on invasive PD in a 5-year cohort of 115 women with CMV primary infection. 3 In this study, we did not observe a significant difference in sensitivity whether AC was performed ≥17 + 0 or ≥20 + 0 WG, as long as the interval between seroconversion and invasive PD was >8 weeks. However, the number of cases with intrauterine transmission and AC before 21 WG was limited. Therefore, we extended our investigation to all cases (n = 2706) with PD for CMV in amniotic fluid (AF) sampled between 17 + 0 and 22 + 6 WG during a 16-year period from 2001 to 2016. Women with multiple pregnancies were excluded from the study. Laboratory diagnosis of CMV primary infection was confirmed in 531 women either by CMV immunoglobulin G (IgG) seroconversion (n = 133) or a positive CMV immunoglobulin M (IgM) test in the presence of low CMV-IgG avidity (n = 398). PD was accomplished by rapid virus culture and/or by quantitative detection of CMV DNA in AF. In 338 cases, adequate specimen were available at termination of pregnancy or at birth for the diagnosis of congenital CMV infection (cCMV). Sixty-three of the 338 pregnancies were part of our previous study. 3 4, 5 In total, an interval of ≤8 weeks and >8 weeks was warranted in 46 and 264 pregnancies, respectively. In 28 cases, the interval could not be determined.
For the 338 cases, we observed an overall sensitivity of PD of 85.2% (95% CI: 77; 91). Sensitivity in the group with an interval of ≤8 weeks (n = 46) and >8 weeks (n = 264) was 58.3% (95% CI: 28; 85) and 89.4% (95% CI: 81; 95), respectively. This difference was statistically significant (p = 0.013; Fisher exact test). In cases with indeterminate interval (n = 28), the sensitivity was 75.0% (95% CI: 19; 99). Rapid virus culture and PCR were concomitantly performed in 320 of 338 AF samples. The agreement between the two assays was 99.7%. The discordant sample (obtained at 18 + 6 WG and ≤8 weeks after seroconversion) was culture negative and PCR positive (36.250 IU/mL) in an infant with confirmed cCMV at birth. Figure 1 shows the results of CMV-DNA detection in AF in pregnancies with an interval of >8 weeks between seroconversion and AC. Negative PD results in pregnancies affected by cCMV occurred at any gestational age. Sensitivity and negative predictive values of AC at 17 + 0 to 20 + 6 WG were not significantly different compared with AC at 21 + 0 to 22 + 6 WG (sensitivity: p = 0.725, negative predictive value: p = 0.497, Fisher exact test; Table 1 ). The same is true if we choose 20 weeks as breakpoint: The difference of sensitivity between AC at 17 + 0 to 19 + 6 (84.2%; 16/19) and AC at 20 + 0 to 22 + 6 (90.9%; 60/66) is not significant (p = 0.412). In pregnancies with an interval of >8 weeks between seroconversion and AC, clinical outcome at birth was known in seven of nine congenitally infected infants with a negative PD (between 17 + 0 and 21 + 1 WG). Six were clinically healthy at term. One infant born at 36 + 5 WG showed signs of lenticulostriate vasculopathy on brain ultrasound but was otherwise healthy. In pregnancies with ≤8 weeks or an unknown interval between seroconversion and AC, cCMV was diagnosed in six cases following negative PD. Five of the six infants were born at term. Outcome at birth was unknown in one case. Three infants were asymptomatic, and one child had a traumatic subdural haemorrhage. One infant was delivered by emergency caesarean section after placental abruption at 28 + 4 WG. The newborn presented with severe asphyxia requiring cardiopulmonary resuscitation. The postnatal period was complicated by intraventricular haemorrhage. There was no evidence of CMV disease (such as sensorineural hearing loss, chorioretinitis, intracranial calcifications, ventriculomegaly, polymicrogyria, white matter lesions and cortical atrophy) at birth.
The current 21-week threshold for performing AC has become recommended practice on a scant evidence base. [6] [7] [8] Donner et al. 6 reported a sensitivity of AC before 21 weeks' gestation of 45.4% (5/11). In all six cases with false negative AC, the delay between diagnosis of maternal infection varied from 3 to 8 weeks, and in four of them, gestational age at PD was 14 to 16 weeks. Gouarin et al. 7 found an overall sensitivity of 72.4% (21/29). Gestational age at AC and delay between seroconversion and AC were only reported for the eight wrongly negative cases. In two of the four cases with AC before 22 WG (at 16, 17, 19.5 and 21 WG), the delay was ≤8 weeks. Bodeus et al. 8 observed the best sensitivity (95.5%; 21/22) for AC at ≥23 weeks and a delay of ≥6 weeks between AC and first IgM positive serum. AC at ≤22 weeks (delay of ≥6 weeks) resulted in a lower sensitivity (76.9%, 10/13), but the difference did not reach statistical significance. In women with AC ≤22 weeks, the exact gestational age at PD was not reported. Analysing both factors concomitantly, Bodeus et al. concluded that, for optimal sensitivity, the delay between AC and seroconversion was more important than gestational age. Accordingly, we observed in our present study no significant difference for sensitivity of PD whether AC was performed at 17 + 0 to 20 + 6 WG or at 21 + 0 to 22 + 6 WG, as long as the interval was >8 weeks. Importantly, none of the infants with cCMV after negative PD and available information on clinical outcome at birth presented with severe CMV disease. This is in concordance with the findings of Bilavsky et al. 9 who reported that infants born with cCMV after negative AC (>20/21 full WG) seldom present with mild clinical symptoms or cerebral ultrasound features. Prenatal diagnosis at an earlier gestational age is welcome for several reasons: In case of a positive result, fetal treatment may be started before irreversible cerebral damage has occurred. 10 If considered appropriate, termination of pregnancy can be performed clearly before the age of fetal viability. In contrast, a negative PD result may allow early reassurance of parents. In view of the limited evidence of the current recommendations, our present findings and the anticipated favourable outcome in infants with cCMV after a negative AC give reasons for a prospective study on this subject. In our cohort, AF samples obtained from 17 + 0 to 17 + 6 yielded 'false negative' results in two of four infected fetuses. We therefore suggest to prospectively compare the diagnostic sensitivity of AC performed at 18 + 0 to 18 + 6 versus 21 + 0 to 21 + 6 WG in women with a laboratory confirmed primary infection around conception and the early first trimester (i.e. unequivocal CMV-IgG seroconversion before 10 + 0 WG). At least as important as the question of diagnostic sensitivity of AC should be the clinical follow-up of infants with cCMV infection and negative PD. Finally, if children with cCMV after negative AC at 18 + 0 to 18 + 6 WG have the same clinical outcome as those with negative AC >21 WG, some loss in sensitivity might be acceptable in favour of an earlier PD.
